Library · Oncology, infection & imaging · Intraoperative imaging of ovarian cancer
Pegulicianine
Lumisight
An FDA-approved (2024) fluorescent imaging agent used during breast-cancer surgery to spot residual tumor tissue after lumpectomy. It stays dark until tumor-associated enzymes activate it, and paired with the Lumicell system it reached about 84% diagnostic accuracy in the Phase 3 INSITE trial.
Research score 87/100. Reference only, not a dose.
- Diagnostic Imaging
- Surgical Guidance
- US status
- Prescription Only - Diagnostic
- Approval
- FDA Approved (2024)
- Evidence
- INSITE Phase 3 (406 patients): 84% diagnostic accuracy in detecting residual cancer real-time
- Research score
- 87 / 100
- Indication
- Intraoperative fluorescence imaging of residual breast cancer
- Origin
- United States
- Source category
- Diagnostic & Imaging
- Status group
- Approved / prescription
Mechanism
An inactive prodrug linking a fluorophore and quencher is cleaved by tumor-overexpressed cathepsins and matrix metalloproteinases, separating the two components and producing a fluorescent signal in cancerous tissue.
Safety file
Well tolerated for its imaging role.
- Minimal - typical for imaging agents